<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843386</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2008-03</org_study_id>
    <nct_id>NCT02843386</nct_id>
  </id_info>
  <brief_title>Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma</brief_title>
  <acronym>FOTEADJ</acronym>
  <official_title>Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After the local treatment of the primary tumor (protonbeam-therapy, enucleation, external
      radiotherapy) patients with high risk of metastasis are randomized between:

        -  Adjuvant chemotherapy with Fotemustin.

        -  Observation

      Both groups are followed during 3 years for Metastasis- Free Survival, safety and tolerance
      of Fotemustin, quality of life, and Overall Survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High risk uveal melanoma is defined by :

        -  Clinical criteria: Largest Tumor Diameter ≥ 15 mm with extra scleral extension and/or
           retinal detachment or Largest Tumor Diameter ≥ 18 mm AND/ OR

        -  Genomic high risk signature (aCGH +/-LOH): Monosomy 3 or partial deletion of 3p
           associated with any 8 gain.

      Treatment schedule :

        -  Induction: Fotemustin 100 mg/m², D1-D8-D15, 1 hour IV infusion, 1 cycle

        -  Maintenance : restart on D50, Fotemustine : 100 mg/m², 1 hour IV infusion, D1 D21, 5
           cycles.

      Both groups are followed during 3 years for Metastasis- Free Survival, safety and tolerance
      of Fotemustin, quality of life, and Overall Survival.

      Note :Based on the second interim analysis showing futility, and no chance to observe any
      significant statistical difference at the end of the study, the Independent Data Monitoring
      Committee recommended to stop randomization and amend the protocol to propose an
      interventional surveillance to high-risk patients as per protocol (April 2016).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 23, 2009</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-Free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time between patient randomization and metastases occurrence or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time between patient randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : incidence of Adverse Events and Serious Adverse Events and laboratory abnormalities</measure>
    <time_frame>3 years</time_frame>
    <description>using National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) V3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Baseline, 6 months and 3 years</time_frame>
    <description>Using QLQ-C30 questionary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>A : Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant chemotherapy by Fotemustin 100mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : Surveillance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intensive surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy by Fotemustin</intervention_name>
    <description>Fotemustin is given for 6 cycles :
One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.
Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21.</description>
    <arm_group_label>A : Chemotherapy</arm_group_label>
    <other_name>Fotemustin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive surveillance</intervention_name>
    <description>Intensive surveillance
Total duration: 3 years.
liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months.</description>
    <arm_group_label>B : Surveillance</arm_group_label>
    <other_name>Surveillance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. High risk uveal melanoma, defined by :

               -  Clinical criteria: Largest Tumor Diameter ≥ 15 mm with extrascleral extension
                  and/or retinal detachment or Largest Tumor Diameter ≥ 18 mm AND/OR

               -  Genomic high risk signature (cCGH +/- LOH) : Monosomy 3 or partial deletion of 3p
                  and any 8 gain, from enucleation, transscleral or transvitreal samples

          2. Age ≥ 18 years and ECOG Performance Status ≤ 2

          3. No prior chemotherapy or history of invasive cancer &lt; 5years

          4. No metastases

          5. Local treatment for the primary tumour (surgery and/or radiotherapy) achieved ≤ 30
             days from randomization, chemotherapy to begin within 15 days.

        6 - Contraception in women of child-bearing potential

        7- Written informed consent

        8- Patients with French Social Security in compliance with the French law relating to
        biomedical research.

        Non-Inclusion Criteria:

          1. Largest Tumor Diameter &lt; 15 mm or Largest Tumor Diameter 15-18 mm without extrascleral
             extension and/or retinal detachment, in the absence of genomic alteration as defined
             per protocol or in the absence of Fine Needle Aspiration biopsy for genomic risk
             assessment.

          2. Contraindication to Fotemustine administration

          3. Hematological function : Hb &lt; 10g/dL, absolute neutrophil count &lt; 2,000/mm3, and
             platelets &lt; 100,000/mm3

          4. Biochemistry results :Total bilirubin and AST/ALT &gt; 1,5 UNL (Upper Normal Limit)

          5. Creatinine &gt; 1,5 UNL (Upper Normal Limit)

          6. Pregnant and/or breastfeeding women.

        8 - Previous history of cancer excepting in situ cervical carcinoma or cutaneous basal
        carcinoma.

        7- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
        infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
        arrhythmia, viral or other hepatitis or cirrhosis, or psychiatric illness/social situation
        that would interfere with the protocol or limit compliance with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie PIPERNO-NEUMANN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveal melanoma</keyword>
  <keyword>High risk of metastasis</keyword>
  <keyword>Genomic high risk signature</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

